The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 1179-1182

  Andersen, Maibritt B ^a   Werge, Thomas ^a   Fink Jensen, Anders ^b  

^a Sct Hans Hospital   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DEXAMPHETAMINE; GALANTAMINE;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL SYMPTOM; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; SEDATION; STEREOTYPY; VOMITING;

ANIMALS; AROUSAL; BEHAVIOR, ANIMAL; CEBUS; CHOLINESTERASE INHIBITORS; DEXTROAMPHETAMINE; DYSKINESIA, DRUG-INDUCED; DYSTONIA; GALANTAMINE; HYPOKINESIA; LOCOMOTION; MALE; PSYCHOMOTOR AGITATION; PSYCHOSES, SUBSTANCE-INDUCED; SLEEP STAGES; STEREOTYPED BEHAVIOR; TIME FACTORS;

EID: 34248579635     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.119677     Document Type: Article

References (33)

1. Allen TB and McEvoy JP (2002) Galantamine for treatment-resistant schizophrenia. Am J Psychiatry 159:1244-1245.
2. Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA, and Werge T (2003) The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 28:1168-1175.
3. Andersen MB, Fuxe K, Werge T, and Gerlach J (2002) The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav Pharmacol 13:639-644.
4. Birrell CE and Balfour DJ (1998) The influence of nicotine pretreatment on mesoaccumbens dopamine overflow and locomotor responses to D-amphetamine. Psychopharmacology (Berl) 140:142-149.
5. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465-473.
6. Bora E, Veznedaroglu B, and Kayahan B (2005) The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 28:139-141.
7. Brandt-Christensen M, Andersen MB, Fink-Jensen A, Werge T, and Gerlach J (2006) The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys. J Neural Transm 113:11-19.
8. 125I]-alpha-bungarotoxin binding in human post mortem brain. J Comp Neurol 387:385-398.
9. Buchanan RW, Summerfelt A, Tek C, and Gold J (2003) An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59:29-33.
10. Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Mitch CH, Ward JS, Calligaro DO, Ludvigsen TS, Sheardown MJ, Olesen PH, et al. (1998) Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] octane. Eur J Pharmacol 356:109-119.
11. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, and Perry E (1999) Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: α-bungarotoxin and nicotine binding in the thalamus. J Neurochem 73:1590-1597.
12. Crook JM, Tomaskovic-Crook E, Copolov DL, and Dean B (2001) Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158:918-925.
13. Dean B, Crook JM, Opeskin K, Hill C, Keks N, and Copolov DL (1996) The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1:54-58.
14. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, and Light GA (2005) Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol 28:179-184.
15. Fink-Jensen A (2000) Novel pharmacological approaches to the treatment of schizophrenia. Dan Med Bull 47:151-167.
16. Fink-Jensen A, Kristensen P, Shannon HE, Calligaro DO, DeLapp NW, Whitesitt C, Ward JS, Thomsen C, Rasmusseen T, Sheardown MJ, et al. (1998) Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats. Neuroreport 9:3481-3486.
17. Freedman R, Hall M, Adler LE, and Leonard S (1995) Evidence in post mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38:22-33.
18. Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C, and Goff DC (2005) Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 181:358-363.
19. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, and Davis KL (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51:349-357.
20. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, and Tonegawa S (2001) Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 98:15312-15317.
21. Gerlach J and Casey DE (1990) Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. Prog Neuropsychopharmacol Biol Psychiatry 14:103-112.
22. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, Shannon H, Xia B, Deng C, and Wess J (1999) Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96:10483-10488.
23. Hikida T, Kitabatake Y, Pastan I, and Nakanishi S (2003) Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc Natl Acad Sci USA 100:6169-6173.
24. Kumari V, Aasen I, ffytche D, Williams SC, and Sharma T (2006) Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. Neuroimage 29:545-556.
25. Mendelsohn E, Rosenthal M, Bohiri Y, Werber E, Kotler M, and Strous RD (2004) Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. Int Clin Psychopharmacol 19:319-324.
26. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, et al. (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630-638.
27. Peacock L and Gerlach J (1993) Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol. Eur J Pharmacol 237:329-340.
28. Rosse RB and Deutsch SI (2002) Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 25:272-275.
29. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, et al. (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024-1036.
30. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen L, Sheardown MJ, Sauerberg P, and Fink-Jensen A (2000) Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 42:249-259.
31. Simosky JK, Stevens KE, and Freedman R (2002) Nicotinic agonists and psychosis. Curr Drug Targets CNS Neurol Disord 1:149-162.
32. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, et al. (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299:782-792.
33. Tuǧal O, Yazici KM, Anil Yagcioglu AE, and Gogus A (2004) A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 7:117-123.